177 related articles for article (PubMed ID: 36313331)
1. Insights into the roles and driving forces of CCT3 in human tumors.
Ma J; Song P; Liu X; Ma C; Zheng M; Ren X; Wang R; Liu W; Lu Z; Li J
Front Pharmacol; 2022; 13():1005855. PubMed ID: 36313331
[TBL] [Abstract][Full Text] [Related]
2. Pan-Cancer Analysis of the Roles and Driving Forces of RAB42.
Zheng M; Wang W; Bu Y; Liu J; Ma J; Wang R; Ren X; Lu Z; Li J; Cai J
Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671428
[TBL] [Abstract][Full Text] [Related]
3. Clinical and prognostic value of chaperonin containing T-complex 1 subunit 3 in hepatocellular carcinoma: A Study based on microarray and RNA-sequencing with 4272 cases.
Hou JY; Wu HY; He RQ; Lin P; Dang YW; Chen G
Pathol Res Pract; 2019 Jan; 215(1):177-194. PubMed ID: 30473171
[TBL] [Abstract][Full Text] [Related]
4. Suppression of CCT3 inhibits melanoma cell proliferation by downregulating CDK1 expression.
Liu W; Zhang X; Chen C; Li Y; Yang C; Han Z; Jiang G; Liu Y
J Cancer; 2022; 13(6):1958-1971. PubMed ID: 35399722
[TBL] [Abstract][Full Text] [Related]
5. Identification of CCT3 as a prognostic factor and correlates with cell survival and invasion of head and neck squamous cell carcinoma.
Wang Y; Liu P; Zhang Z; Wang J; Cheng Z; Fan C
Biosci Rep; 2021 Oct; 41(10):. PubMed ID: 34505628
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of CCT3 promotes cervical cancer progression through FN1.
Dou L; Zhang X
Mol Med Rep; 2021 Dec; 24(6):. PubMed ID: 34651664
[TBL] [Abstract][Full Text] [Related]
7. Exploring the oncogenic roles of LINC00857 in pan-cancer.
Ren X; Liu J; Wang R; Liu X; Ma X; Lu Z; Hu Z; Zheng M; Ma J; Li J
Front Pharmacol; 2022; 13():996686. PubMed ID: 36160408
[TBL] [Abstract][Full Text] [Related]
8. Chaperonin containing TCP-1 subunit 3 is critical for gastric cancer growth.
Li LJ; Zhang LS; Han ZJ; He ZY; Chen H; Li YM
Oncotarget; 2017 Dec; 8(67):111470-111481. PubMed ID: 29340068
[TBL] [Abstract][Full Text] [Related]
9. Current understanding on the role of CCT3 in cancer research.
Liu W; Lu Y; Yan X; Lu Q; Sun Y; Wan X; Li Y; Zhao J; Li Y; Jiang G
Front Oncol; 2022; 12():961733. PubMed ID: 36185198
[TBL] [Abstract][Full Text] [Related]
10. CCT3 acts upstream of YAP and TFCP2 as a potential target and tumour biomarker in liver cancer.
Liu Y; Zhang X; Lin J; Chen Y; Qiao Y; Guo S; Yang Y; Zhu G; Pan Q; Wang J; Sun F
Cell Death Dis; 2019 Sep; 10(9):644. PubMed ID: 31501420
[TBL] [Abstract][Full Text] [Related]
11. Pan-cancer analysis of super enhancer-induced PRR7-AS1 as a potential prognostic and immunological biomarker.
Wang R; Liu N; Li G; Liu J; Ma X; Liu X; Li J
Front Genet; 2023; 14():1160599. PubMed ID: 37091809
[No Abstract] [Full Text] [Related]
12. Overexpression of chaperonin containing TCP1, subunit 3 predicts poor prognosis in hepatocellular carcinoma.
Cui X; Hu ZP; Li Z; Gao PJ; Zhu JY
World J Gastroenterol; 2015 Jul; 21(28):8588-604. PubMed ID: 26229401
[TBL] [Abstract][Full Text] [Related]
13. Chaperonin containing TCP1 subunit 3 (CCT3) promotes cisplatin resistance of lung adenocarcinoma cells through targeting the Janus kinase 2/signal transducers and activators of transcription 3 (JAK2/STAT3) pathway.
Danni X; Jiangzheng Z; Huamao S; Yinglian P; Changcheng Y; Yanda L
Bioengineered; 2021 Dec; 12(1):7335-7347. PubMed ID: 34612768
[TBL] [Abstract][Full Text] [Related]
14. CCT3 suppression prompts apoptotic machinery through oxidative stress and energy deprivation in breast and prostate cancers.
Temiz E; Koyuncu İ; Sahin E
Free Radic Biol Med; 2021 Mar; 165():88-99. PubMed ID: 33508424
[TBL] [Abstract][Full Text] [Related]
15. Suppression of CCT3 Inhibits Tumor Progression by Impairing ATP Production and Cytoplasmic Translation in Lung Adenocarcinoma.
Chen S; Tian Y; Ju A; Li B; Fu Y; Luo Y
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409343
[TBL] [Abstract][Full Text] [Related]
16. Suppression of CCT3 inhibits the proliferation and migration in breast cancer cells.
Xu G; Bu S; Wang X; Zhang H; Ge H
Cancer Cell Int; 2020; 20():218. PubMed ID: 32518527
[TBL] [Abstract][Full Text] [Related]
17. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
18. Integrated bioinformatics and experiments reveal the roles and driving forces for HSF1 in colorectal cancer.
Ren X; Zhang L; Ma X; Li J; Lu Z
Bioengineered; 2022 Feb; 13(2):2536-2552. PubMed ID: 35006040
[TBL] [Abstract][Full Text] [Related]
19. SEMA6B Overexpression Predicts Poor Prognosis and Correlates With the Tumor Immunosuppressive Microenvironment in Colorectal Cancer.
Li T; Yan Z; Wang W; Zhang R; Gan W; Lv S; Zeng Z; Hou Y; Yang M
Front Mol Biosci; 2021; 8():687319. PubMed ID: 34938771
[No Abstract] [Full Text] [Related]
20.
Wu G; Chen M; Ren H; Sha X; He M; Ren K; Qi J; Lin F
Front Cell Dev Biol; 2022; 10():930933. PubMed ID: 35874816
[No Abstract] [Full Text] [Related]
[Next] [New Search]
